1. Home
  2. ABVX vs CACC Comparison

ABVX vs CACC Comparison

Compare ABVX & CACC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABVX
  • CACC
  • Stock Information
  • Founded
  • ABVX 2013
  • CACC 1972
  • Country
  • ABVX France
  • CACC United States
  • Employees
  • ABVX N/A
  • CACC N/A
  • Industry
  • ABVX
  • CACC Finance: Consumer Services
  • Sector
  • ABVX
  • CACC Finance
  • Exchange
  • ABVX Nasdaq
  • CACC Nasdaq
  • Market Cap
  • ABVX 5.3B
  • CACC 6.3B
  • IPO Year
  • ABVX N/A
  • CACC 1992
  • Fundamental
  • Price
  • ABVX $84.01
  • CACC $474.44
  • Analyst Decision
  • ABVX Strong Buy
  • CACC Sell
  • Analyst Count
  • ABVX 8
  • CACC 2
  • Target Price
  • ABVX $90.63
  • CACC $475.00
  • AVG Volume (30 Days)
  • ABVX 1.2M
  • CACC 112.5K
  • Earning Date
  • ABVX 08-11-2025
  • CACC 10-29-2025
  • Dividend Yield
  • ABVX N/A
  • CACC N/A
  • EPS Growth
  • ABVX N/A
  • CACC 143.69
  • EPS
  • ABVX N/A
  • CACC 34.75
  • Revenue
  • ABVX $7,073,400.00
  • CACC $1,173,200,000.00
  • Revenue This Year
  • ABVX $25.23
  • CACC $157.70
  • Revenue Next Year
  • ABVX N/A
  • CACC $3.60
  • P/E Ratio
  • ABVX N/A
  • CACC $13.64
  • Revenue Growth
  • ABVX N/A
  • CACC 43.92
  • 52 Week Low
  • ABVX $4.77
  • CACC $414.16
  • 52 Week High
  • ABVX $92.91
  • CACC $560.00
  • Technical
  • Relative Strength Index (RSI)
  • ABVX 67.94
  • CACC 38.35
  • Support Level
  • ABVX $82.72
  • CACC $507.41
  • Resistance Level
  • ABVX $91.30
  • CACC $526.40
  • Average True Range (ATR)
  • ABVX 3.62
  • CACC 16.47
  • MACD
  • ABVX -1.13
  • CACC -1.60
  • Stochastic Oscillator
  • ABVX 47.89
  • CACC 1.95

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

About CACC Credit Acceptance Corporation

Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.

Share on Social Networks: